COVID-19 vaccine by the FDA has sparked significant discussion due to its restrictive usage guidelines. Unlike the Pfizer and Moderna vaccines, which have received full approval for broader populations, Novavax's authorization is confined to adults aged 65 and older and individuals between 12 and 64 with underlying health conditions that heighten their risk of severe COVID-19 . This limitation appears to stem from market research indicating that these demographics are more likely to seek vaccination .
FDA has approved Novavax’s Covid-19 vaccine for individuals 65 and older, and those 12 and up with underlying conditions that increase their risk of severe illness. Novavax President and CEO John Jacobs stated this approval aligns with market research and CDC data indicating these populations are most likely to seek seasonal Covid-19 vaccination, representing a significant step in making their protein-based vaccine available. The CDC lists numerous conditions, including older age, asthma, diabetes, lung disease, obesity, and pregnancy, as factors increasing the risk of severe Covid-19.
mRNA vaccines prompt the patient to produce small amounts of virus to help create an immune response while the Adjuvanted has a protein spike to create the coupled with a Matrix-M adjuvant to prompt an immune response.
The company submitted its product for approval on April 1 along with Phase 3 clinical trial data, the press release said.
Novavax originally showed its vaccine was safe and effective in a 30,000-person clinical trial. The FDA had been on track to grant Novavax full approval – without restrictions — by its April 1 target date, according to two people with direct knowledge of the situation who spoke on condition of anonymity to discuss confidential agency matters.
Novavax later announced the FDA instead was asking it to run an additional trial after approval, which is highly unusual. FDA did order several additional trials to be completed in the next few years, some examining whether the vaccine might be associated with some heart conditions. Another required study must assess the benefits of continuing vaccination in 50- to 64-year-olds who don’t have health problems that increase their risk from COVID-19.
Furthermore, the FDA's decision comes after a substantial delay and contrasts sharply with initial expectations for unrestricted approval following successful clinical trials involving approximately 30,000 participants . The agency has mandated additional trials to ascertain the vaccine’s efficacy in younger populations without increased risk factors. These developments raise questions about regulatory consistency and potential political influences on public health decisions .
Read more 
Chinese factory output defies tariffs, retail sales falter Wall Street Futures Drop Amid Concerns Over U.S. Credit Rating CutSarah H
Also on site :